Results 21 to 30 of about 113,904,810 (178)

Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy? [PDF]

São Paulo Medical Journal, 2009
Carlos Eduardo Paiva, Bianca Sakamoto Ribeiro Paiva, Odair Carlito Michelin   +2 more
doaj   +4 more sources

Casopitant: a novel NK1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting

Therapeutics and Clinical Risk Management, 2009
Christina Ruhlmann, Jørn HerrstedtOdense University Hospital, Department of Oncology, Odense, DenmarkAbstract: Chemotherapy-induced nausea and vomiting (CINV) are among the most feared and distressing symptoms experienced by patients with ...
Christina Ruhlmann, Jørn Herrstedt   +1 more
doaj   +1 more source

Neurokinin 1 receptor antagonist along with dexamethasone reduces the inflammation in COVID-19 patients: a novel therapeutic approach [PDF]

, 2023
Background: Corona virus infection is a respiratory infection, compromising the normal breathing in critical patients by damaging the lungs. The aim of this study was to evaluate the clinical outcomes of Substance P receptor Neurokinin 1 antagonist in ...
Shahid, Imran, Mehboob, Riffat, Qayyum, Ahad, Ahmad, Fridon Jawad, Tamur, Shadi, Rana, Muhammad Asim, Abusikkuen, Samy A., Fathaddin, Amany, Mirza, Iman M, Zayed, Mohamed A, Tariq, Muhammad Akram   +10 more
core   +1 more source

Substance P and NK-1R in Dengue: A First Serological Investigation. [PDF]

Health Sci Rep
ABSTRACT Background Dengue fever lacks reliable biomarkers to explain its complex pathophysiology. Substance P (SP) and its receptor, the Neurokinin‐1 receptor (NK1R), known regulators of inflammation and vascular permeability in viral infections, may play a role in dengue but remain unexplored. Aim/Objective To investigate the levels of SP and NK1R in
Mehboob R, Shahid I, Ahmad S, Sarwar N, John A, Mehboob Z, Almansouri M, Badoghaish W.   +7 more
europepmc   +2 more sources

Efficacy of the neurokinin‐1 receptor antagonist aprepitant in children with cyclical vomiting syndrome [PDF]

Alimentary Pharmacology & Therapeutics, 2014
SummaryBackgroundAprepitant (Emend, Merck Sharp & Dohme Ltd, Haarlem, the Netherlands), a neurokinin‐1 receptor antagonist, prevents vomiting in a range of conditions. No data are available on its use in children with cyclical vomiting syndrome (CVS).AimWe investigated the efficacy of aprepitant as prophylactic treatment or acute intervention ...
F, Cristofori, N, Thapar, E, Saliakellis, N, Kumaraguru, M, Elawad, F, Kiparissi, J, Köglmeier, P, Andrews, K J, Lindley, O, Borrelli   +9 more
openaire   +2 more sources

Broadening the View: Substance P and Its Metabolism in Pruritus-Related Diseases. [PDF]

J Dermatol
ABSTRACT Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues.
Walter T, Burckhardt BB.
europepmc   +2 more sources

The in vitro anti‐cancer synergy of neurokinin‐1 receptor antagonist, aprepitant, and 5‐aminolevulinic acid in glioblastoma

BioFactors, 2023
AbstractGlioblastoma multiforme (GBM) is the most malignant type of cerebral neoplasm in adults with a poor prognosis. Currently, combination therapy with different anti‐cancer agents is at the forefront of GBM research. Hence, this study aims to evaluate the potential anti‐cancer synergy of a clinically approved neurokinin‐1 receptor antagonist ...
Safieh Ebrahimi, Farshad Mirzavi, Seyed Isaac Hashemy, Maryam Khaleghi Ghadiri, Walter Stummer, Ali Gorji   +5 more
openaire   +2 more sources

Cancer-related pain: A bidirectional modulator of cancer progression. [PDF]

Clin Transl Med
CRP and tumour progression engage in a dynamic, bidirectional circuit mediated by multiple mechanisms involving neuroimmunology and cancer ‐neuroscience. Analgesic interventions may affect tumour progression, while anticancer therapies can influence pain. Targeting pain in cancer may have promising therapeutic value in cancer progression.
He J, Zhang Y, Liu Q, Yan B, Chai P, Jia R.   +5 more
europepmc   +2 more sources

The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer

International Journal of Oncology, 2014
The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in the development of cancer. No in-depth studies of the involvement of this system in breast cancer (BC) have been carried out, and the action exerted by the drug aprepitant on BC cells is currently unknown.
Miguel, Muñoz, Ana, González-Ortega, Manuel Vicente, Salinas-Martín, Andrés, Carranza, Susana, Garcia-Recio, Vanessa, Almendro, Rafael, Coveñas   +6 more
openaire   +3 more sources

Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals [PDF]

AIDS, 2010
Neurokinin-1 receptor (NK1R) antagonists interfere with binding of neuropeptide substance P to NK1R and exhibit novel anti-HIV-1 activities. Since NK1R antagonists effectively penetrate the blood-brain barrier to reduce the inflammatory response within the brain, we wished to evaluate their potential as anti-HIV-1 candidates for targeting HIV-1 ...
Mark M, Manak, Dmitry A, Moshkoff, Lequan T, Nguyen, John, Meshki, Pablo, Tebas, Florin, Tuluc, Steven D, Douglas   +6 more
openaire   +2 more sources